-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today (October 9), a biomedical company dedicated to new cell therapy and stem cell research-Suzhou Xueji Biotechnology Co.
Completed tens of millions of angel round financing, jointly led by Weidu Investment and Yuanhe Holdings
The founder of Xueji Biology is Dr.
Public information shows that Xueji Bio uses platelets produced in vitro as its lead product to solve the urgently needed platelet demand in diseases such as cancer, liver disease, acute and critical illness, and hematological diseases.
Using platelets produced in vitro as the lead product, we will also develop innovative drugs for various diseases related to platelet abnormalities, focusing on the in vitro regeneration of different cells in the blood system and immune system generated by the differentiation of hematopoietic stem cells.
Image source: Baotu.
Dr.
The relevant person in charge of Weidu Investment commented: "Xueji is committed to the innovative clinical application of new generation stem cell technology, which is expected to fill the gap in the global market and has a huge market space
The person in charge of Yuanhe Holdings’ project said: “Yuanhe Holdings is very pleased to participate in the angel round investment of Xueji Biology